Clinical Trial Results:
A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant
Summary
|
|
EudraCT number |
2011-003019-47 |
Trial protocol |
DE HU PL CZ ES BE EE FI SE GB |
Global end of trial date |
27 Mar 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Sep 2018
|
First version publication date |
21 Feb 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
SPD489-329
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01436175 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Shire Development LLC
|
||
Sponsor organisation address |
725 Chesterbrook Boulevard Wayne, Pennsylvania, United States, 19087
|
||
Public contact |
Medical Communications, Shire Pharmaceuticals Ltd, +44 0800 0556614, medinfoglobal@shire.com
|
||
Scientific contact |
Medical Communications, Shire Pharmaceuticals Ltd, +44 0800 0556614, medinfoglobal@shire.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 Mar 2014
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
27 Mar 2014
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective was to evaluate the long-term safety and tolerability of SPD489 administered as a daily morning dose (20, 30, 50, and 70 milligram per day [mg/day]) as adjunctive therapy to an antidepressant for the treatment of major depressive disorder (MDD) in adults (18-65 years of age inclusive at the time of consent for the respective short-term antecedent SPD489 MDD study). Long-term safety was described using:
• Occurrence of treatment-emergent adverse events (TEAEs),
• Responses to the Columbia Suicide Severity Rating Scale (C-SSRS), and
• Specific evaluation of blood pressure and pulse rate, clinical laboratory evaluations, and electrocardiogram (ECG) results.
|
||
Protection of trial subjects |
This study was conducted in accordance with International Conference on Harmonisation (ICH) of Good Clinical Practice (GCP), the principles of the Declaration of Helsinki, as well as other applicable local ethical and legal requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
27 Feb 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Poland: 20
|
||
Country: Number of subjects enrolled |
Spain: 6
|
||
Country: Number of subjects enrolled |
United Kingdom: 1
|
||
Country: Number of subjects enrolled |
Czech Republic: 83
|
||
Country: Number of subjects enrolled |
Estonia: 24
|
||
Country: Number of subjects enrolled |
Finland: 8
|
||
Country: Number of subjects enrolled |
Germany: 69
|
||
Country: Number of subjects enrolled |
Hungary: 4
|
||
Country: Number of subjects enrolled |
United States: 1190
|
||
Country: Number of subjects enrolled |
Mexico: 27
|
||
Country: Number of subjects enrolled |
Canada: 36
|
||
Country: Number of subjects enrolled |
Romania: 8
|
||
Country: Number of subjects enrolled |
South Africa: 5
|
||
Country: Number of subjects enrolled |
Chile: 33
|
||
Country: Number of subjects enrolled |
Argentina: 27
|
||
Country: Number of subjects enrolled |
Australia: 13
|
||
Country: Number of subjects enrolled |
Croatia: 5
|
||
Worldwide total number of subjects |
1559
|
||
EEA total number of subjects |
228
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
1559
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||
Recruitment details |
Study enrolled eligible adults with MDD who had completed treatment in a short-term antecedent SPD489 (lisdexamfetamine dimesylate) MDD study (SPD489-209 [2011-003615-28], SPD489-322 [2011-003018-17], and SPD489-323 [2011-003006-25]). | ||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||
Screening details |
A total of 1570 subjects were enrolled. Of these, 11 subjects excluded from the Safety Analysis Set (reasons for discontinuation were 3 subjects lost to follow up, 3 subject withdrew and 5 subjects were without a post-Visit 0 safety assessment). A total of 1559 subjects were included in Safety Analysis Set. | ||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||
Period 1 title |
Overall Trial (overall period)
|
||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||
Arm title
|
SPD489 + Antidepressant | ||||||||||||||||||||||
Arm description |
SPD489 20, 30, 50 or 70 mg once daily orally for 52 weeks along with the assigned background product that subject had received during the antecedent study (antidepressant: either escitalopram oxalate, sertraline hydrochloride [HCl], venlafaxine HCl extended-release, or duloxetine HCl) at a dose consistent with applicable local labeling guidelines. | ||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||
Investigational medicinal product name |
lisdexamfetamine dimesylate (LDX)
|
||||||||||||||||||||||
Investigational medicinal product code |
SPD489
|
||||||||||||||||||||||
Other name |
Vyvanse, Venvanse, Elvanse, Tyvense
|
||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||
Dosage and administration details |
SPD489 20, 30, 50 or 70 mg once daily orally for 52 weeks along with the assigned background product that subject had received during the antecedent study.
|
||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
SPD489 + Antidepressant
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
SPD489 20, 30, 50 or 70 mg once daily orally for 52 weeks along with the assigned background product that subject had received during the antecedent study (antidepressant: either escitalopram oxalate, sertraline hydrochloride [HCl], venlafaxine HCl extended-release, or duloxetine HCl) at a dose consistent with applicable local labeling guidelines. | ||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
SPD489 + Antidepressant
|
||
Reporting group description |
SPD489 20, 30, 50 or 70 mg once daily orally for 52 weeks along with the assigned background product that subject had received during the antecedent study (antidepressant: either escitalopram oxalate, sertraline hydrochloride [HCl], venlafaxine HCl extended-release, or duloxetine HCl) at a dose consistent with applicable local labeling guidelines. |
|
|||||||||||
End point title |
Columbia-Suicide Severity Rating Scale (C-SSRS) [1] | ||||||||||
End point description |
C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviour during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Safety analysis set included all subjects who took at least 1 dose of investigational product and had at least 1 post-Visit 0 (Week 0) safety assessment in this study.
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
Week 5 up to Week 52/Early Termination(ET)
|
||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Since this is a single arm study, no statistical analysis was planned. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change From Baseline in Systolic Blood Pressure at Week 52 [2] | ||||||||||||
End point description |
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 [2011-003615-28], SPD489-322 [2011-003018-17], and SPD489-323 [2011-003006-25]).
Safety Analysis Set. Here n = subjects evaluable at specified time-points.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline, Week 52/ET
|
||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Since this is a single arm study, no statistical analysis was planned. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change From Baseline in Diastolic Blood Pressure at Week 52 [3] | ||||||||||||
End point description |
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 [2011-003615-28], SPD489-322 [2011-003018-17], and SPD489-323 [2011-003006-25]).
Safety Analysis Set. Here n = subjects evaluable at specified time-points.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline, Week 52/ET
|
||||||||||||
Notes [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Since this is a single arm study, no statistical analysis was planned. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change From Baseline in Pulse Rate at Week 52 [4] | ||||||||||||
End point description |
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 [2011-003615-28], SPD489-322 [2011-003018-17], and SPD489-323 [2011-003006-25]).
Safety Analysis Set. Here n = subjects evaluable at specified time-points.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline, Week 52/ET
|
||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Since this is a single arm study, no statistical analysis was planned. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 52/ET | ||||||||||||
End point description |
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 [2011-003615-28], SPD489-322 [2011-003018-17], and SPD489-323 [2011-003006-25]).
Full Analysis Set (FAS) included all subjects in the Safety Analysis Set who had at least 1 clinical experience outcome assessment in the study. Here n = subjects evaluable at specified time-points.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Baseline, Week 52/ET
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Number of Subjects With Improvement on Clinical Global Impressions - Global Improvement (CGI-I) | ||||||||
End point description |
Subjects who did not have Clinical Global Impressions - Severity of Illness (CGI-S) assessed at Week 8 in the antecedent study should not have had CGI-I assessed in this study and were excluded from the summary of CGI-I. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 52/ET
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Short Form-12 Health Survey Version 2 (SF-12V2) | ||||||||||||
End point description |
SF-12V2 is a multi-purpose, 7-item survey that measures 8 domains of health: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. It is expressed by two summary measures (Aggregate Physical and Aggregate Mental) for which values can range from 0 to 100. A higher score is indicative of a better health state.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Mobility | ||||||||||||||||
End point description |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Self-Care | ||||||||||||||||
End point description |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Usual Activities | ||||||||||||||||
End point description |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Pain/Discomfort | ||||||||||||||||
End point description |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Anxiety/Depression | ||||||||||||||||
End point description |
Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale | ||||||||
End point description |
EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. EQ-5D-5L Visual Analog Scale score is numbered from 0 to 100, where a score of 100 is the best health a subject can imagine.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Week 52/ET
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR) | ||||||||||
End point description |
QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression. The QIDS-SR was only assessed in the SPD489-322 antecedent study. The QIDS-SR total score is calculated as the sum of the highest score on any 1 of Items 1-4, Item 5, the highest score on any 1 of Items 6-9, Items 10-14, the highest score on either Item 15 or 16.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
Week 52/ET
|
||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF) | ||||||||||||||
End point description |
The Q-LES-Q-SF is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and their treatment. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total raw score (summary scale score) was calculated by summing item scores 1 to 14 (total raw score range: 14 to 70). Item 15 (satisfaction with medication, raw score range: 1 to 5) and Item 16 (overall satisfaction and contentment; raw score range: 1 to 5) were stand-alone items. For reporting, summary scale, Item 15 and Item 16 raw scores were transformed into percentage maximum possible score which ranged from 0 to 100, where higher scores are indicative of greater enjoyment or satisfaction.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint, n = subjects evaluable for specified categories.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Change From Baseline in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score at Week 52/ET | ||||||||||||||||
End point description |
CSFQ-14 is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 [2011-003615-28], SPD489-322 [2011-003018-17], and SPD489-323 [2011-003006-25]).
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint, n = subjects evaluable for specified categories.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Baseline, Week 52/ET
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Amphetamine Cessation Symptom Assessment (ACSA) Total Score | ||||||||||
End point description |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
Week 53
|
||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Patient Resource Utilization Questionnaire - Major Depressive Disorder (PRUQ-MDD) | ||||||||||||||||||||||||||||||||||||
End point description |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study subjects. Subjects answered the following questions:
1. Were you hospitalized in the past month, 2. Do you work for pay, 3. If you missed time at work last week, please note all the reasons why, 4. Would you say that the past week was typical, like the rest of the 3 weeks this month, in terms of your working hours, 5. Do you do volunteer work (VW), and 6. If you do not receive money for your work and do not participate in volunteer work, the reason is.
Number of subjects with response is reported.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
PRUQ-MDD – Number of Days of Resource Utilization | ||||||||||||||
End point description |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study subjects. Number of nights in medical/surgical ward, number of nights in ICU, and number of days a subject received home care in the past month are reported.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint, n = subjects evaluable for specified categories.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||
End point title |
PRUQ-MDD – Number of Events (Visit to Health Care Provider/Visit to Hospital Facilities/Number of Times a Test Was Performed) | ||||||||||||||||||||||||||||
End point description |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study subjects. Subjects answered following questions - 1. How many times did you visit the following healthcare providers in the past month: Family doctor/primary care, Non-physician healthcare practitioner (NPHP), Psychiatrist/Psychologist/Counselor (PPC); 2. How many times did you take one of the tests, mentioned below, during the past month: Blood test, CT Scan, X Ray, Renal function, Thyroid function; and 3. How many times did you visit the hospital emergency room (ER), urgent care facility (UCF) or an after-hours clinic (AHC) in the past month. Number of events (visit to health care provider, visit to hospital facilities, number of times a test was performed) are reported.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint, n = subjects evaluable for specified categories.
|
||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
PRUQ-MDD – Number of Hours | ||||||||||||||
End point description |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study subjects. Subjects answered following questions - 1. How many hours do you usually work or would you usually be expected to work (hrs/week); 2. How many hours did you actually work last week; 3. On average, how many hours do you volunteer per week. Number of hours are reported.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint, n = subjects evaluable for specified categories.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||||
|
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
PRUQ-MDD – Effect of Depressive Symptoms | ||||||||||||
End point description |
The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study subjects. Subjects answered following questions on a 0 to 10 point scale - 1. During past week, how much did depressive symptoms affect work productivity; 2. During past week, how much did depressive symptoms affect regular non-work daily activities. Higher scores indicates more effect of depressive symptoms on work productivity and non-work daily activities.
FAS. Here, Number of Subjects Analyzed = subjects who were evaluable for this endpoint, n = subjects evaluable for specified categories
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 52/ET
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to Week 53
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
TEAEs were defined as Adverse Events (AEs) that started or deteriorated on or after the date of the first dose of investigational product and no later than 3 days after the last dose of investigational product.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
14.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
SPD489 + Antidepressant
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
SPD489 20, 30, 50 or 70 mg once daily orally for 52 weeks along with the assigned background product that subject had received during the antecedent study (antidepressant: either escitalopram oxalate, sertraline hydrochloride [HCl], venlafaxine HCl extended-release, or duloxetine HCl) at a dose consistent with applicable local labeling guidelines. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
11 Nov 2011 |
Specified that the 4 antidepressants (background product) were to be provided by the sponsor.
Clarified psychiatric disorders that were exclusionary to study participation.
Specified that the systolic and diastolic blood pressure readings were based on an average of 3 readings.
Included medications having Central Nervous System (CNS) effects as being exclusionary to study participation.
Clarified prior use of investigational product, participation in a previous clinical study, and use of commercial LDX as being exclusionary to study participation.
Reduced the duration after the study that a subject was to take contraception from 30 days after the last dose of investigational product to 7 (+2) days.
Specified that the management of blood pressure and pulse during the study were to be based on an average of 3 readings for each respective measurement.
Updated excluded treatments to describe excluded investigational compounds and to add LDX as being an excluded treatment.
Expanded permitted concomitant medications during the study to include any medication (not just over the counter medications or antibiotics) not affecting blood pressure, heart rate, or the CNS and that were considered necessary for the subject’s welfare.
Specified that background product was to be taken in conjunction with investigational product.
Noted which study assessments were to be performed when background product was tapered or investigational product was down-titrated.
Noted that investigational product was to be stored based on the temperature range specified on the label.
Added that eligible subjects who declined participation were not permitted to enroll in the study at a later date.
Updated specific items of interest on the C-SSRS for the investigator to use when evaluating a subject’s suitability to remain in the study.
Updated Q-LES-Q-SF version and date. |
||||||
15 Nov 2012 |
Female subjects must “not have a positive beta-human chorionic gonadotropin (β-hCG)” rather than “must have a negative β-hCG.”
Specified that a female subject’s pregnancy was to be reported within 24 hours.
Updated to include requirements regarding malignancy and skin cancer history exclusion.
Specified that an average QT interval calculated using Fridericia’s formula (QTcF) or QT interval calculated using Bazett’s formula (QTcB) interval greater than (>) 450 millisecond (msec) (males) or >470msec (females) was exclusionary to study participation.
Limited use of prohibited medications to “current use” rather than “current use or prior use (during the antecedent study).”
Removed the requirement that the investigator contact the contract research organization (CRO) medical monitor prior to withdrawal of the subject from investigational product.
Added that, in the opinion of the investigator, changes in physical examination, clinical laboratory, or ECG results precluding treatment with SPD489 would require the subject to discontinue from the study.
Specified that subjects requiring a change in MDD treatment prohibited by the protocol were discontinued from the study.
Specified intervals for QTcF and QTcB for which a subject would be excluded.
The following reasons for discontinuation were added under the category of “other”:
– Change in background product for MDD treatment required, Treatment for MDD, or any other condition, by a prohibited medication, Other reasons for discontinuation (must be specified)
Added that occasional non-chronic use of sedatives and anxiolytics was permitted.
Updated window for Visit 0 (Dose Optimization) study assessments for subjects not entering this study directly from the pre-defined antecedent study. Also specified that these subjects must have signed informed consent prior to these assessments being done. |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |